| **Eligibility Term**                                                  | **Neurological Disorder Type** | **Category**           | **% of Trials (in category)** | **Inclusion/Exclusion** | **FHIR Resource**   | **Code (LOINC/SNOMED/ICD)** | **Unstructured EMR Example**                                                     |
| --------------------------------------------------------------------- | ------------------------------ | ---------------------- | ----------------------------- | ----------------------- | ------------------- | --------------------------- | -------------------------------------------------------------------------------- |
| MMSE score between 22 and 30                                          | Alzheimer's Disease            | Cognitive Assessment   | 83.3%                         | Inclusion               | Observation         | LOINC: 72107-6              | Mini-Mental State Examination (MMSE) score was 24 at screening.                  |
| Positive amyloid PET scan                                             | Alzheimer's Disease            | Imaging                | 66.7%                         | Inclusion               | ImagingStudy        | SNOMED: 441652000           | Amyloid PET imaging revealed elevated amyloid deposition.                        |
| Clinical Dementia Rating (CDR) score of 0.5 to 1.0                    | Alzheimer's Disease            | Cognitive Assessment   | 75.0%                         | Inclusion               | Observation         | LOINC: 54626-8              | CDR score was assessed as 0.5 indicating very mild dementia.                     |
| Apolipoprotein E (ApoE) genotyping                                    | Alzheimer's Disease            | Genetic                | 41.7%                         | Inclusion               | Observation         | LOINC: 21641-9              | Patient consented to ApoE genetic testing for AD risk.                           |
| Uncontrolled hypertension                                             | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | Condition           | ICD-10: I10                 | Hypertension not managed with medication, BP >170/100.                           |
| Significant cerebrovascular disease                                   | Alzheimer's Disease            | Diagnosis              | 50.0%                         | Exclusion               | Condition           | ICD-10: I67.89              | MRI indicates evidence of chronic cerebrovascular ischemia.                      |
| Stable use of symptomatic AD medications                              | Alzheimer's Disease            | Treatment History      | 66.7%                         | Inclusion               | MedicationStatement | SNOMED: 430193006           | Patient has been on donepezil 10mg for over 3 months.                            |
| History of stroke or TIA within 1 year                                | Alzheimer's Disease            | Diagnosis              | 58.3%                         | Exclusion               | Condition           | ICD-10: I63.9               | Patient had a minor stroke 8 months ago.                                         |
| Study partner available for the duration of the trial                 | Alzheimer's Disease            | Caregiver/Support      | 91.7%                         | Inclusion               | RelatedPerson       | SNOMED: 224291000000109     | Patient's spouse agreed to accompany them to all clinic visits as study partner. |
| History of psychiatric illness (e.g., major depression, psychosis)    | Alzheimer's Disease            | Psychiatric History    | 83.3%                         | Exclusion               | Condition           | ICD-10: F33.1               | Patient had a diagnosis of major depressive disorder 6 months ago.               |
| Contraindications to MRI (e.g., metal implants, pacemakers)           | Alzheimer's Disease            | Imaging                | 75.0%                         | Exclusion               | Procedure           | SNOMED: 433146000           | MRI contraindicated due to presence of pacemaker.                                |
| Evidence of abnormal liver or renal function                          | Alzheimer's Disease            | Lab                    | 50.0%                         | Exclusion               | Observation         | LOINC: 24323-8              | Elevated liver enzymes noted in baseline labs.                                   |
| History of alcohol or substance abuse in past 1–2 years               | Alzheimer's Disease            | Lifestyle Factors      | 75.0%                         | Exclusion               | Condition           | ICD-10: F10.10              | Patient reports alcohol dependence until last year.                              |
| Use of investigational drug within past 6 months                      | Alzheimer's Disease            | Treatment History      | 58.3%                         | Exclusion               | MedicationStatement | SNOMED: 428181000124101     | Subject previously enrolled in trial involving investigational BACE inhibitor.   |
| Adequate vision and hearing to complete assessments                   | Alzheimer's Disease            | Functional Status      | 41.7%                         | Inclusion               | Observation         | SNOMED: 397540003           | Hearing and visual acuity adequate for neuropsych testing.                       |
| Pregnant or breastfeeding                                             | Alzheimer's Disease            | Reproductive           | 25.0%                         | Exclusion               | Observation         | LOINC: 11449-6              | Pregnancy test positive at baseline screening.                                   |
| Age between 50 and 90 years                                           | Alzheimer's Disease            | Demographics           | 83.3%                         | Inclusion               | Patient             | SNOMED: 397669002           | Patient is 72 years old at time of screening.                                    |
| Diagnosis of probable Alzheimer's Disease or MCI due to AD            | Alzheimer's Disease            | Diagnosis              | 91.7%                         | Inclusion               | Condition           | SNOMED: 26929004            | Clinical diagnosis of mild cognitive impairment due to Alzheimer’s Disease.      |
| Abnormal memory function (e.g., WMS-R LM II or equivalent)            | Alzheimer's Disease            | Cognitive Assessment   | 75.0%                         | Inclusion               | Observation         | LOINC: 72106-8              | Logical Memory II recall score was below normal range for age.                   |
| Participation in another monoclonal antibody therapy trial            | Alzheimer's Disease            | Treatment History      | 50.0%                         | Exclusion               | MedicationStatement | SNOMED: 428181000124101     | Previously enrolled in a monoclonal antibody trial targeting amyloid.            |
| Stable dose of Alzheimer’s medications for at least 8–12 weeks        | Alzheimer's Disease            | Treatment History      | 66.7%                         | Inclusion               | MedicationStatement | SNOMED: 430193006           | On donepezil 10mg for past 3 months without dose change.                         |
| Positive biomarker for brain amyloid pathology (PET/CSF/plasma)       | Alzheimer's Disease            | Biomarker              | 66.7%                         | Inclusion               | Observation         | SNOMED: 441652000           | CSF Aβ42 levels below threshold consistent with AD pathology.                    |
| Major systemic illness not under control (cardiac, hepatic, renal)    | Alzheimer's Disease            | Clinical               | 58.3%                         | Exclusion               | Condition           | ICD-10: R69                 | Patient has poorly controlled heart failure with recent hospitalization.         |
| Body Mass Index (BMI) between 17 and 35                               | Alzheimer's Disease            | Vitals                 | 33.3%                         | Inclusion               | Observation         | LOINC: 39156-5              | BMI calculated at 26.7 during screening visit.                                   |
| No other neurodegenerative diseases (e.g., Parkinson’s, Huntington’s) | Alzheimer's Disease            | Diagnosis              | 66.7%                         | Exclusion               | Condition           | ICD-10: G20                 | History of Parkinson’s disease ruled out at screening.                           |
| No evidence of intracranial mass or lesions (e.g., glioma, contusion) | Alzheimer's Disease            | Imaging                | 58.3%                         | Exclusion               | ImagingStudy        | SNOMED: 271442000           | Brain MRI showed no space-occupying lesions or tumors.                           |
| No history of seizures within past 12 months                          | Alzheimer's Disease            | Diagnosis              | 41.7%                         | Exclusion               | Condition           | ICD-10: G40.909             | No seizures reported in last year.                                               |
| No contraindicated medications (e.g., methyldopa, neuroleptics)       | Alzheimer's Disease            | Medication History     | 50.0%                         | Exclusion               | MedicationStatement | SNOMED: 182834006           | Patient discontinued neuroleptics 6 weeks before screening.                      |
| No unstable cardiovascular disease (e.g., angina, CHF)                | Alzheimer's Disease            | Clinical               | 66.7%                         | Exclusion               | Condition           | ICD-10: I50.9               | Patient has stable coronary artery disease and no recent angina.                 |
| Hamilton Depression Rating Scale ≤ 12                                 | Alzheimer's Disease            | Psychiatric Assessment | 25.0%                         | Inclusion               | Observation         | LOINC: 89261-2              | HAM-D score was 9 at baseline screening.                                         |
| No history of clinically significant head trauma                      | Alzheimer's Disease            | Diagnosis              | 41.7%                         | Exclusion               | Condition           | ICD-10: S06.9               | No head trauma events noted in patient history.                                  |
| Normal thyroid function                                               | Alzheimer's Disease            | Lab                    | 33.3%                         | Inclusion               | Observation         | LOINC: 3016-3               | TSH level was 2.0 uIU/mL, within normal range.                                   |
| Informant confirms gradual memory decline over 6–12 months            | Alzheimer's Disease            | Cognitive Assessment   | 50.0%                         | Inclusion               | Observation         | SNOMED: 386806002           | Caregiver reports patient's memory has worsened over the past year.              |
| No active infection or systemic illness in past 30 days               | Alzheimer's Disease            | Clinical               | 33.3%                         | Exclusion               | Condition           | SNOMED: 87628006            | No fevers, cough, or infections documented in past month.                        |
| Willing and able to comply with protocol procedures                   | Alzheimer's Disease            | Behavioral/Compliance  | 75.0%                         | Inclusion               | Patient             | SNOMED: 722912009           | Patient and caregiver agreed to attend all follow-up visits.                     |
| Consent provided by participant or legal representative               | Alzheimer's Disease            | Administrative         | 100.0%                        | Inclusion               | Consent             | SNOMED: 32485007            | Written informed consent obtained from participant’s legal guardian.             |
| No vitamin B12 deficiency or clinically significant low levels        | Alzheimer's Disease            | Lab                    | 25.0%                         | Exclusion               | Observation         | LOINC: 2132-9               | Vitamin B12 level was 550 pg/mL — within normal range.                           |
| Stable use of non-AD medications ≥4 weeks prior to baseline           | Alzheimer's Disease            | Treatment History      | 41.7%                         | Inclusion               | MedicationStatement | SNOMED: 419474003           | Blood pressure meds stable for 6 weeks prior to screening.                       |
| No recent surgery requiring general anesthesia                        | Alzheimer's Disease            | Surgical History       | 25.0%                         | Exclusion               | Procedure           | SNOMED: 52734007            | No major surgery noted in past 3 months.                                         |
| No suicidal ideation or recent psychiatric hospitalization            | Alzheimer's Disease            | Psychiatric History    | 33.3%                         | Exclusion               | Condition           | SNOMED: 19160003            | No suicidal thoughts or psychiatric admission in last 6 months.                  |
| No brain hemorrhage or bleeding disorder                              | Alzheimer's Disease            | Imaging                | 50.0%                         | Exclusion               | Condition           | ICD-10: I61.9               | MRI showed no signs of intracranial bleeding or hemorrhage.                      |
| No uncontrolled diabetes mellitus                                     | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | Condition           | ICD-10: E11.9               | HbA1c was 10.2%; patient excluded due to uncontrolled diabetes.                  |
| No anticoagulation therapy other than low-dose aspirin                | Alzheimer's Disease            | Medication History     | 33.3%                         | Exclusion               | MedicationStatement | SNOMED: 428191000124101     | Patient on warfarin—excluded due to anticoagulant use.                           |
| No HIV infection                                                      | Alzheimer's Disease            | Diagnosis              | 25.0%                         | Exclusion               | Condition           | ICD-10: B20                 | HIV test negative at screening.                                                  |
| Females must not be breastfeeding                                     | Alzheimer's Disease            | Reproductive           | 25.0%                         | Exclusion               | Observation         | LOINC: 63894-1              | Participant denied current breastfeeding during medical interview.               |
| No evidence of ARIA-E on MRI                                          | Alzheimer's Disease            | Imaging                | 16.7%                         | Exclusion               | ImagingStudy        | SNOMED: 248200007           | MRI at week 116 showed no ARIA-E or edema-like changes.                          |
| No major depression per DSM or GDS > 8                                | Alzheimer's Disease            | Psychiatric Assessment | 33.3%                         | Exclusion               | Observation         | LOINC: 48535-2              | GDS score of 9—excluded due to depressive symptoms.                              |
| No use of systemic corticosteroids within 3 months                    | Alzheimer's Disease            | Medication History     | 25.0%                         | Exclusion               | MedicationStatement | SNOMED: 373994007           | Prednisone therapy ended 1 month ago—exclusion criterion met.                    |
| Adequate premorbid intellectual functioning                           | Alzheimer's Disease            | Cognitive Assessment   | 33.3%                         | Inclusion               | Observation         | SNOMED: 248234009           | Participant’s premorbid IQ estimated to be in average range.                     |
| No participation in anti-amyloid immunotherapy trials                 | Alzheimer's Disease            | Treatment History      | 41.7%                         | Exclusion               | MedicationStatement | SNOMED: 763760008           | Not previously enrolled in any anti-amyloid immunotherapy study.                 |
| No history of systemic cancer within last 5 years                     | Alzheimer's Disease            | Clinical               | 33.3%                         | Exclusion               | Condition           | ICD-10: C80.1               | No cancer treatment history reported within past 5 years.                        |
| No obstructive pulmonary disease or asthma                            | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | Condition           | ICD-10: J44.9               | No history of COPD or reactive airway disease.                                   |
| No significant gastrointestinal disorder (e.g., ulcers, bleeding)     | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | Condition           | ICD-10: K25.9               | Patient denied any history of ulcer-related GI bleeding.                         |
| No known hypersensitivity to investigational treatment                | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | AllergyIntolerance  | SNOMED: 420134006           | No allergic reactions to monoclonal antibodies reported.                         |
| No lacunar infarcts in critical brain regions                         | Alzheimer's Disease            | Imaging                | 33.3%                         | Exclusion               | ImagingStudy        | SNOMED: 274100004           | MRI showed no infarcts in thalamus or basal ganglia.                             |
| No exposure to lecanemab                                              | Alzheimer's Disease            | Treatment History      | 25.0%                         | Exclusion               | MedicationStatement | SNOMED: 1087911000119102    | Confirmed that subject was never dosed with lecanemab.                           |
| No current use of memantine                                           | Alzheimer's Disease            | Medication History     | 25.0%                         | Exclusion               | MedicationStatement | SNOMED: 387287000           | Memantine therapy stopped 3 months prior to screening.                           |
| No active suicidal ideation or attempt in past 6 months               | Alzheimer's Disease            | Psychiatric History    | 33.3%                         | Exclusion               | Observation         | SNOMED: 6471006             | No recent suicidal behavior or hospitalization recorded.                         |
| No hypersensitivity to monoclonal antibody treatments                 | Alzheimer's Disease            | Allergy/Intolerance    | 33.3%                         | Exclusion               | AllergyIntolerance  | SNOMED: 91936005            | No allergic history to therapeutic antibodies like BAN2401.                      |
| No participation in investigational drug trials within 30 days        | Alzheimer's Disease            | Treatment History      | 33.3%                         | Exclusion               | MedicationStatement | SNOMED: 428181000124101     | Last investigational therapy ended more than 2 months ago.                       |
| No G6PD deficiency                                                    | Alzheimer's Disease            | Lab                    | 16.7%                         | Exclusion               | Observation         | LOINC: 32532-2              | G6PD test result within normal reference range.                                  |
| No acute respiratory failure                                          | Alzheimer's Disease            | Clinical               | 8.3%                          | Exclusion               | Condition           | ICD-10: J96.00              | No history or symptoms of respiratory failure found.                             |
| No methemoglobinemia or sensitivity to methylthioninium               | Alzheimer's Disease            | Allergy/Intolerance    | 8.3%                          | Exclusion               | AllergyIntolerance  | SNOMED: 444075003           | No prior methemoglobinemia or adverse reaction to methylene blue.                |
| No clinically significant ECG abnormalities                           | Alzheimer's Disease            | Cardiac/Vitals         | 25.0%                         | Exclusion               | Observation         | LOINC: 11524-6              | Baseline ECG within normal sinus rhythm and intervals.                           |
| Women of childbearing potential must use contraception                | Alzheimer's Disease            | Reproductive           | 25.0%                         | Inclusion               | Observation         | SNOMED: 410942007           | Patient advised to use effective contraception during the study.                 |
| MRI must be free of significant lesions or abnormalities              | Alzheimer's Disease            | Imaging                | 41.7%                         | Inclusion               | ImagingStudy        | SNOMED: 274100004           | MRI showed no clinically significant structural abnormalities.                   |
| No unstable hepatic or renal disease                                  | Alzheimer's Disease            | Clinical               | 33.3%                         | Exclusion               | Condition           | ICD-10: K76.9               | Liver function stable; no evidence of active hepatic disease.                    |
| Completion of prior core study phase                                  | Alzheimer's Disease            | Administrative         | 16.7%                         | Inclusion               | Procedure           | SNOMED: 386053000           | Subject completed all visits in core phase before joining extension.             |
| Absence of severe visual or hearing impairment                        | Alzheimer's Disease            | Functional Status      | 25.0%                         | Inclusion               | Observation         | SNOMED: 248234002           | Hearing and vision tested adequate for neuropsychological tasks.                 |
| Must have ≥1 study partner with weekly contact                        | Alzheimer's Disease            | Caregiver/Support      | 58.3%                         | Inclusion               | RelatedPerson       | SNOMED: 224291000000109     | Participant’s daughter lives with her and is available for visits.               |
| No ongoing immunoglobulin or immunosuppressant therapy                | Alzheimer's Disease            | Treatment History      | 33.3%                         | Exclusion               | MedicationStatement | SNOMED: 428731000124106     | No immunosuppressive therapy recorded in the past 6 months.                      |
| Subject must be fluent in study-approved language                     | Alzheimer's Disease            | Administrative         | 16.7%                         | Inclusion               | Patient             | SNOMED: 417163006           | Participant fluent in English and passed language comprehension screening.       |
| Subject must be ambulatory or mobile with aid                         | Alzheimer's Disease            | Functional Status      | 33.3%                         | Inclusion               | Observation         | SNOMED: 16584000            | Patient is mobile with walker and able to attend study visits.                   |
| No ongoing substance abuse                                            | Alzheimer's Disease            | Psychiatric History    | 41.7%                         | Exclusion               | Condition           | ICD-10: F19.10              | Patient has no reported alcohol or drug dependence in the past year.             |
| No history of epilepsy or seizure disorder                            | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | Condition           | ICD-10: G40.909             | No reported episodes of seizures or epilepsy since childhood.                    |
| No severe heart failure (NYHA Class III/IV)                           | Alzheimer's Disease            | Cardiac/Vitals         | 16.7%                         | Exclusion               | Condition           | ICD-10: I50.9               | Heart failure classified as NYHA Class II, eligible for study.                   |
| No long QT syndrome or QTc > 470 ms                                   | Alzheimer's Disease            | Cardiac/Vitals         | 16.7%                         | Exclusion               | Observation         | LOINC: 80288-6              | Baseline ECG QTc was 455 ms—within allowed range.                                |
| No neurological condition other than AD                               | Alzheimer's Disease            | Diagnosis              | 58.3%                         | Exclusion               | Condition           | ICD-10: G31.84              | No diagnosis of Parkinson’s, stroke, or frontotemporal dementia.                 |
| No MRI contraindications (e.g., pacemaker, metal implants)            | Alzheimer's Disease            | Imaging                | 41.7%                         | Exclusion               | Procedure           | SNOMED: 433146000           | No pacemakers, clips, or implants found—MRI safe to perform.                     |
| No clinically significant thyroid dysfunction                         | Alzheimer's Disease            | Lab                    | 25.0%                         | Exclusion               | Observation         | LOINC: 11579-0              | TSH and free T4 were within normal limits.                                       |
| Age ≥ 50 years                                                        | Alzheimer's Disease            | Demographic            | 91.7%                         | Inclusion               | Patient             | LOINC: 30525-0              | Patient is 68 years old—meets age eligibility criteria.                          |
| No current enrollment in other interventional trials                  | Alzheimer's Disease            | Administrative         | 50.0%                         | Exclusion               | Procedure           | SNOMED: 386053000           | Not participating in any other active investigational study.                     |
| Willingness to undergo lumbar puncture or PET scan                    | Alzheimer's Disease            | Procedure              | 25.0%                         | Inclusion               | Procedure           | SNOMED: 302199004           | Patient agreed to lumbar puncture for CSF biomarker analysis.                    |
| Stable medical condition for at least 3 months                        | Alzheimer's Disease            | Clinical               | 41.7%                         | Inclusion               | Condition           | SNOMED: 162607003           | No significant changes in medication or clinical events in past 3 months.        |
| No active CNS infection or demyelinating disease                      | Alzheimer's Disease            | Diagnosis              | 25.0%                         | Exclusion               | Condition           | ICD-10: G04.90              | No evidence of CNS inflammation or multiple sclerosis.                           |
| Mini-Mental State Examination (MMSE) 18–26                            | Alzheimer's Disease            | Cognitive Assessment   | 83.3%                         | Inclusion               | Observation         | LOINC: 72107-6              | MMSE score at baseline was 23.                                                   |
| Diagnosis of probable Alzheimer's dementia per NIA-AA                 | Alzheimer's Disease            | Diagnosis              | 91.7%                         | Inclusion               | Condition           | SNOMED: 26929004            | Clinical diagnosis consistent with probable AD per NIA-AA guidelines.            |
| Consent provided by patient or legally authorized representative      | Alzheimer's Disease            | Administrative         | 100.0%                        | Inclusion               | Consent             | SNOMED: 11341000146104      | Written informed consent signed by caregiver and patient.                        |
| Clinical Dementia Rating (CDR) global score 0.5–1.0                   | Alzheimer's Disease            | Cognitive Assessment   | 50.0%                         | Inclusion               | Observation         | LOINC: 54829-9              | CDR global score of 0.5 confirmed during baseline screening.                     |
| Availability of amyloid PET scan or CSF biomarker confirmation        | Alzheimer's Disease            | Imaging                | 66.7%                         | Inclusion               | Observation         | LOINC: 72509-4              | Amyloid PET scan positive for beta-amyloid deposition.                           |
| Geriatric Depression Scale (GDS) score ≤ 6                            | Alzheimer's Disease            | Psychiatric Assessment | 33.3%                         | Inclusion               | Observation         | LOINC: 44261-6              | Patient scored 4 on GDS—within acceptable range for inclusion.                   |
| No major untreated sleep disorder                                     | Alzheimer's Disease            | Clinical               | 25.0%                         | Exclusion               | Condition           | ICD-10: G47.00              | No symptoms consistent with obstructive sleep apnea or insomnia.                 |
| No known autosomal dominant Alzheimer's mutations                     | Alzheimer's Disease            | Genetic                | 25.0%                         | Exclusion               | Observation         | LOINC: 94309-2              | No PSEN1, PSEN2, or APP mutations identified on genetic screening.               |
| No enrollment in prior study with investigational anti-Aβ therapy     | Alzheimer's Disease            | Treatment History      | 25.0%                         | Exclusion               | MedicationStatement | SNOMED: 763760008           | Not previously enrolled in any anti-amyloid beta antibody study.                 |
| Availability of caregiver to assist in study protocol                 | Alzheimer's Disease            | Caregiver/Support      | 66.7%                         | Inclusion               | RelatedPerson       | SNOMED: 224291000000109     | Spouse committed to supporting patient through study procedures.                 |
| No participation in any prior lecanemab study                         | Alzheimer's Disease            | Treatment History      | 25.0%                         | Exclusion               | MedicationStatement | SNOMED: 1087911000119102    | Subject confirmed to be lecanemab-naïve.                                         |
